Investment
Features
FeesSafety
Academy
More
Pluang+

Tron Inc. shares near Nasdaq $1 minimum, risking delisting process start

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Tron Inc. shares near Nasdaq $1 minimum, risking delisting process start

Tron Inc. shares are trading just above Nasdaq's $1 minimum bid price, close to triggering a compliance review that could lead to delisting if the price stays below $1 for 30 days. The stock is down 50% from its peak this year. Tron Inc., which holds over $250 million in TRON cryptocurrency and has a market cap above $500 million, may consider a reverse stock split to boost its share price temporarily. The company recently partnered with Clear Street to facilitate share sales to clients, aiming to stabilize its stock position.

Tron Inc. shares near Nasdaq's $1 threshold provide context for cryptocurrency market activity on Pluang as of Oct 20, 2026 08:21 WIB. Among 50 major cryptocurrencies, 16 rose and 33 fell today. Notable movers include BAL (Balancer) at Rp16.297 with a 1-day change of +11.14%, BAT (Basic Attention Token) at Rp3.444 with a 1-day change of +9.20% and a near-even Pluang order activity split, and EOS (EOS.IO) at Rp12.649 with a 1-day change of +8.13%.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...

Market News
Bullish
4 hours ago
Bitway drops 16% while Worldcoin rises 9.3%, marking a volatile 24-hour crypto session.

Bitway drops 16% while Worldcoin rises 9.3%, marking a volatile 24-hour crypto session.

In the latest 24-hour crypto market update, Bitway experienced the largest drop, falling 16% to $1.96 with a market cap of $2.94 billion. Conversely, Worldcoin led gains with a 9.29% rise to $0.5344 and a market cap of $2.04 billion. Other notable ga...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App